• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Blood reviews >Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
【24h】

Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

机译：B细胞淋巴瘤中的基因组特征：如何提高诊断的准确性并告知预后？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current genomic technologies have immensely improved disease classification and prognostication of major sub-types of B-cell lymphomas. This novel genetic information has not only aided in diagnosis, but has also revealed a landscape of critical molecular events that determine the biological and clinical behavior of a lymphoma. In this review, we summarized the genetic characteristics of major subtypes of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL). We illustrated how genomic profiling had identified molecular subgroups in DLBCL with varied clinical outcomes, and how a subset of genes defined prognosis in MCL and aided in BL diagnoses. We also highlighted some Phase clinical trials using new therapeutic agents to determine clinical efficacy in novel molecular subgroups with distinct gene expression patterns. We believe that refinement of genomic signatures will require more intensive efforts from the biomedical research community to improve targeted therapy designs and bring a substantial change in the treatment decisions. In the next era of genomic medicine, we anticipate that a clinically and biologically relevant molecular profile of each tumor will be obtained at diagnosis to guide therapy. (C) 2015 Published by Elsevier Ltd.
机译：当前的基因组技术极大地改善了B细胞淋巴瘤主要亚型的疾病分类和预后。这种新颖的遗传信息不仅有助于诊断，而且还揭示了决定淋巴瘤生物学和临床行为的关键分子事件。在这篇综述中，我们总结了B细胞淋巴瘤的主要亚型的遗传特征，包括弥漫性大B细胞淋巴瘤（DLBCL），滤泡性淋巴瘤（FL），伯基特淋巴瘤（BL）和套细胞淋巴瘤（MCL）。我们举例说明了基因组概况分析如何在DLBCL中鉴定出具有不同临床结果的分子亚组，以及基因的一个子集如何定义MCL的预后并有助于BL诊断。我们还重点介绍了一些使用新治疗剂的阶段性临床试验，以确定具有独特基因表达模式的新型分子亚组的临床疗效。我们认为，基因组特征的完善将需要生物医学研究界做出更深入的努力，以改善目标疗法的设计并带来重大的治疗决策改变。在基因组医学的下一个时代，我们预计在诊断时将获得每种肿瘤的临床和生物学相关分子概况，以指导治疗。 （C）2015由Elsevier Ltd.出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号